Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion

Summary

This is a phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study with additional multiple-ascending dose cohorts in healthy male and female volunteers.

Timeline

Start

2012-01

Primary completion

2012-07

Completion

2012-07

Outcome

Outcome not reported

Stopped: “Corporate decision to reformulate the investigational product.”

Drugs

Indications